Business Context and Reporting Period
Company: Takeda Pharmaceutical Company Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 19, 2021
Subject: Corporate Governance Report
Reporting Period: The filing updates governance structures and policies effective as of the filing date, with specific data points referencing the fiscal year ended March 2021 and the fiscal year 2020.
Key Financial Metrics
This filing is a Corporate Governance Report and does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures for the current period. The document explicitly directs investors to the quarterly results and Investor Relations section of the company website for financial metrics and management guidance.
Capital Structure Data Provided:
- Foreign Shareholding Ratio: More than 30% (as of end of March 2021).
- Major Shareholders (Top 3): The Master Trust Bank of Japan, Ltd. (9.55%), Custody Bank of Japan, Ltd. (5.34%), and The Bank of New York Mellon (4.98%).
- Controlling Shareholder: None.
Material Changes and Governance Updates
The filing details significant updates to the company's governance framework and compliance status:
- Corporate Governance Code Compliance: The company is in compliance with all principles of the Corporate Governance Code (effective June 1, 2018). A revised report based on the new Code (effective June 11, 2021) is scheduled for submission by December 2021.
- Board Composition: The Board consists of 16 Directors, 12 of whom are Independent External Directors (including 4 Audit and Supervisory Committee Members). The Board is chaired by an Independent External Director.
- Audit and Supervisory Committee (ASC): As of June 2021, the ASC consists entirely of External Directors to enhance independence.
- Committee Structure: The Nomination Committee and Compensation Committee are established as advisory bodies to the Board, composed entirely of External Directors and chaired by External Directors.
- System Abolitions: The company abolished the advisor system in July 2017 and the corporate counselor system in March 2021.
Guidance, Outlook, and Management Commentary
Strategic Focus: The company's purpose is "Better Health for People, Brighter Future for the World." Management is pursuing a framework appropriate for an R&D-driven biopharmaceutical company, focusing on agile decision-making, internal controls, and compliance.
Compensation Policy Updates:
- Performance-Based Pay: Internal Directors (excluding External Directors) receive a mix of Basic Compensation, Short-Term Incentives (Bonus), and Long-Term Incentives (Stock Compensation). The ratio of Long-Term Incentives was increased in FY2019 to better align with shareholder interests.
- Clawback Policy: A recoupment policy was adopted in 2020, effective April 1, 2020. It allows the Board to recoup incentive compensation from Internal Directors in the event of a significant financial restatement or significant misconduct.
- External Directors: Compensation consists of Basic Compensation and Long-Term Incentives linked only to share price (not financial performance). No bonuses are available for this group.
Sustainability and ESG: The company achieved carbon neutrality (Scopes 1, 2, and 3) starting with FY2019 emissions and commits to being carbon zero without offsets in Scopes 1 and 2 by 2040.
Investor Verification Checklist
- Financial Performance: Verify the latest quarterly results and fiscal year 2021 management guidance (revenue, Core Operating Profit, EPS) on the Takeda Investor Relations website, as these figures are not in this filing.
- Board Independence: Confirm the continued independence of the 12 External Directors and the composition of the Audit and Supervisory Committee.
- Compensation Alignment: Review the specific KPIs used for the Long-Term Incentive Plan (revenue, free cash flow, R&D targets) to ensure alignment with long-term shareholder value.
- Clawback Policy Implementation: Monitor the application of the 2020 clawback policy in the event of any future financial restatements.
- Shareholder Rights: Note the electronic voting platform usage and the absence of anti-takeover measures.